TargetMol

Risperidone

Product Code:
 
TAR-T0351
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0351-10mg10mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0351-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0351-25mg25mg£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0351-50mg50mg£139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0351-100mg100mg£175.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0351-200mg200mg£248.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0351-500mg500mg£373.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Risperidone is a selective blocker of dopamine D2 receptors and serotonin 5-HT2 receptors that act as an atypical antipsychotic agent.
CAS:
106266-06-2
Formula:
C23H27FN4O2
Molecular Weight:
410.493
Pathway:
Membrane transporter/Ion channel; Neuroscience; GPCR/G Protein
Purity:
0.9951
SMILES:
Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12
Target:
Dopamine Receptor; 5-HT Receptor; Adrenergic Receptor; P-gp

References

1. Angelucci F, et al. J Neurosci Res,2000, 60(6), 783-794. 2. Tarazi FI, et al. J Pharmacol Exp Ther,2001, 297(2), 711-717. 3. Kato T, et al. Schizophr Res,2007, 92(1-3), 108-115. 4. Zhu HJ, et al. Neuropsychopharmacology,2007, 32(4), 757-764. 5. Baptista T, et al. Brain Res,2002, 957(1), 144-151.